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Abstract 
Checkpoint kinase 1 (CHK1) is a key mediator of the DNA damage response that 
regulates cell cycle progression, DNA damage repair and DNA replication. Small-
molecule CHK1 inhibitors sensitise cancer cells to genotoxic agents and have shown 
single agent preclinical activity in cancers with high levels of replication stress. 
However, the underlying genetic determinants of CHK1 inhibitor sensitivity remain 
unclear. We used the developmental clinical drug SRA737 in an unbiased large-
scale siRNA screen to identify novel mediators of CHK1 inhibitor sensitivity and 
uncover potential combination therapies and biomarkers for patient selection. We 
identified members of the B-family of DNA polymerases (POLA1, POLE and POLE2) 
whose silencing sensitised the human A549 non small cell lung cancer (NSCLC) and 
SW620 colorectal cancer cell lines to SRA737. B-family polymerases were validated 
using multiple siRNAs in a panel of NSCLC and colorectal cancer cell lines. 
Replication stress, DNA damage and apoptosis were increased in human cancer 
cells following depletion of the B-family DNA polymerases combined with SRA737 
treatment. Moreover, pharmacological blockade of B-family DNA polymerases using 
aphidicolin or CD437 combined with CHK1 inhibitors led to synergistic inhibition of 
cancer cell proliferation. Furthermore, low levels of POLA1, POLE and POLE2 
protein expression in NSCLC and colorectal cancer cells correlated with single agent 
CHK1 inhibitor sensitivity and may constitute biomarkers of this phenotype. These 
findings provide a potential basis for combining CHK1 and B-family polymerase 
inhibitors in cancer therapy.  
Statement of Significance 
Findings demonstrate how the therapeutic benefit of CHK1 inhibitors may potentially 
be enhanced and could have implications for patient selection and future 
development of new combination therapies. 
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Introduction 
DNA is routinely subject to exogenous or endogenous sources of damage (1). 
Therefore, cells have evolved complex surveillance mechanisms, known as cell 
cycle checkpoints, to tightly regulate the cell cycle and maintain genomic integrity 
(2,3). In normal cells, these checkpoints are activated in response to DNA damage, 
so that cell cycle progression can be co-ordinated with the detection and repair of 
damaged DNA to prevent genomic instability. In cancer cells, these cell cycle 
checkpoints are frequently deregulated, leading to high levels of replication stress 
and genomic instability, an enabling characteristic of cancer (4,5).  
Replication stress is often described as the slowing or stalling of replication fork 
progression during DNA synthesis and is caused by a number of different factors 
(6,7). As a result of replication fork stalling, DNA polymerases become uncoupled 
from DNA helicases, which continue to unwind the DNA. This DNA unwinding 
generates stretches of single-strand DNA (ssDNA) that are protected by binding of 
replication protein A (RPA; 8). RPA recruits a number of replication stress response 
proteins and is reliant on the ATR-CHK1 pathway to initially stabilise replication forks 
and delay the onset of mitosis until replication is resumed and completed (7,9). 
Checkpoint kinase 1 (CHK1) is a serine/threonine kinase and a critical component of 
several cell cycle checkpoints acting through multiple mechanisms, including 
replication fork stabilisation and repair (10,11). Cancer cells with defects in cell cycle 
control, including those with high levels of replication stress, may therefore be more 
dependent on cell cycle checkpoints and specifically CHK1 for survival (12). Such 
cancer-specific dependency could be exploited for therapeutic gain, making CHK1 
an attractive anticancer target. 
Preclinical validation of CHK1 as a cancer drug target, using siRNA and chemical 
tools, has led to the development of a number of CHK1 inhibitors (13), including the 
highly selective, potent and orally bioavailable clinical drug candidate SRA737 
(14,15), which is undergoing evaluation in phase I clinical trials 
(www.clinicaltrials.gov; NCT02797977, NCT02797964). CHK1 inhibitors have been 
shown to potentiate a number of chemotherapeutic agents (16), in particular 
gemcitabine (17,18), and demonstrate single agent activity in cancer subtypes with 
high levels of replication stress (17,19,20). Despite these observations, the 
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underlying genetic determinants of sensitivity to clinically relevant CHK1 inhibitors 
remain unclear and there are currently no clinically validated biomarkers for patient 
selection. The identification of genes, which are synthetically lethal in combination 
with CHK1 inhibition, could lead to novel drug combination studies and potential 
predictive biomarkers of CHK1 inhibitor sensitivity. This may allow the identification 
of sensitive patient populations and aid the clinical application and evaluation of 
CHK1 inhibitors. 
Synthetic lethality occurs when the simultaneous loss of function of two gene 
products results in cell death but the loss of either alone does not (21). Using the 
clinical drug candidate SRA737, we performed a large-scale synthetic lethal siRNA 
screen in human cancer cells in order to identify those gene products whose loss is 
synthetically lethal with CHK1 inhibition. Here, we show that siRNAs targeting 
POLA1, POLE and POLE2, which encode subunits belonging to the B-family of DNA 
polymerases, are synthetically lethal in combination with CHK1 inhibition in multiple 
human non-small cell lung cancer (NSCLC) and colorectal cancer cell lines, 
suggesting a new potential treatment approach. Moreover, combinatorial depletion of 
the B-family DNA polymerases and small-molecule CHK1 inhibition resulted in 
increased replication stress, DNA damage and cell death. Pharmacological blockade 
of both B-family DNA polymerases and CHK1 led to synergistic inhibition of cancer 
cell proliferation. Furthermore, we show that low POLA1 and POLE protein 
expression may represent biomarkers for single agent CHK1 inhibitor sensitivity.   
Materials and Methods  
Cell lines 
Human cell lines were obtained from the ATCC (USA), except SKLU1, which was 
obtained from the HPA (UK). Lines were validated by DNA profiling and confirmed 
free of Mycoplasma spp. by PCR using the VenorGeM® Mycoplasma PCR detection 
kit (Minerva Labs, UK). All cell lines were purchased more than a year prior to the 
experiments and were propagated for less than three months after thawing. All 
experiments were performed within 10 passages after thawing. NSCLC cell lines 
were cultured in RPMI 1640 supplemented with 10% foetal bovine serum (FBS) and 
colorectal cancer cell lines were cultured in DMEM with 5mM L-glutamine, 1% NEAA 
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and 10% FBS. HBEC3-KT cells were cultured in keratinocyte SFM serum-free 
medium supplemented with human recombinant epidermal growth factor (5 ng/ml) 
and bovine pituitary extract (30 g/ml). Cells were 
atmosphere at 5% CO2.  
Drugs  
SRA737 was synthesised in-house at the ICR (14,15). Aphidicolin and CD437 were 
purchased from Sigma-Aldrich (USA), MK-8776 from Selleck Chemicals (USA) and 
gemcitabine from Eli Lilly (USA). Stock solutions of SRA737, MK-8776, aphidicolin 
and CD437 were prepared in DMSO and a stock solution of gemcitabine was 
prepared in 0.9 % NaCl solution. All stock solutions were stored at -  
Cell lysis and western blotting 
Total cell lysates were prepared as described (22) except that NP40 was increased 
to 0.3%. Protein concentration was determined using a bicinchoninic acid (BCA) 
assay. Cell lysates (10 to 50 µg) were mixed in Laemmli sample buffer and heated 
for -PAGE on pre-cast 3 to 8% tris-
acetate or 10% tris-glycine gels (Invitrogen, USA), at 150 V for 60 to 90 min. Proteins 
were then transferred onto PVDF membranes (Merck Millipore, MA, USA) at 100 V 
for 90 min. Membranes were incubated in 5% milk or 5% BSA in TNT buffer (50 
mmol/L Tris (pH 8.0), 150 mmol/L NaCl and 0.1%Tween 20) for 1 hour at and then 
POLE2 (ab57298), CHK1 pS345 (CST-2348), CHK1 (SC-8408), RPA32 (ab125681), 
cleaved PARP (CST-9541) and GAPDH (ab8245). Membranes were then washed 
and incubated with horseradish peroxidase-conjugated secondary antibodies 
(mouse/rabbit) for 1 hour. Proteins were visualised using enhanced 
chemiluminescence (ECL, Pierce Biotechnology, USA) and hyperfilm (GE 
Healthcare, UK). 
 
Screening with a small interfering RNA library 
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The Dharmacon druggable genome siRNA library (Dharmacon, GE Healthcare Life 
Sciences, UK) consists of siRNAs (four pooled siRNAs per gene) which target the 
expression of 7593 genes that encode known drug targets or potentially druggable 
proteins. Of these 7593 genes, 6371 (84 %) were screened which included the 
kinase, phosphatase and drug targets subsets. Dharmacon druggable human 
genome siRNA library master plates (384-well) containing lyophilised siRNA were re-
suspended in RNAse-free water to a final concentration 
automated Echo® 550 Liquid Handler (Labcyte, USA), 
transferred from a master plate to six 96-well daughter plates, to give a final assay 
concentration of 25 nM. siRNAs were introduced into cells by reverse transfection; 
50 µl of HiPerFect in Opti-MEM (Invitrogen, USA) was added to each well at a final 
assay concentration of 0.3% and incubated for 20 min. Cells (50 µl), at optimum 
seeding density, were then added to each well, incubated for 48 h at 37 ºC and 
treated with SRA737 at the maximum sub-lethal dose (0.4 µM or 0.8 µM for A549 
and SW620, respectively) or DMSO vehicle (0.004 % or 0.008% for A549 and 
SW620, respectively) in 100 µl medium followed by incubation for 84 h at 37 ºC. 
Plates were fixed with 10% trichloroacetic acid and stained with 0.4% 
sulphorhodamine-B (SRB) in 1% acetic acid. SRB was solubilised with 10 mM Tris 
base and plates were read at 490 nm using a Wallac Victor 1420 multilabel counter 
(Perkin-Elmer, USA). Three independent biological repeats of the screen were 
carried out for each cancer cell line. 
Statistical tests: Robust z-score and Z' factor 
A Z'-factor was calculated for the entire screen to ensure a wide assay window for hit 
identification which was maintained (23). Robust Z-scores were calculated to identify 
hits from the screen. The difference in robust Z-score, with and without SRA737, was 
calculated for each siRNA in each biological repeat and averaged. Hits were defined 
as those genes with a difference in robust Z-score greater than or equal to three, 
with the most significant differences given higher priority. Additional selection criteria 
for further hit evaluation were (i) a minimal effect of siRNA alone on cell number and 
(ii) commonality to both cell lines. 
Hit validation: siRNA and protein knockdown 
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Hits were validated using pooled siRNA (Dharmacon, USA) and individual siRNAs 
(Qiagen, USA). HiPerFect was used at 0.3% (A549, SW620 cells) or 0.2% (Calu-6, 
NCI-H1975, RKO and HCT116 cells). HiPerFect in Opti-MEM (40 µl) was added to 
10 µl siRNA in RNAse-free water in each well and incubated for 20 min. Cells (50 µl) 
were then added at the optimal seeding density and incubated for 48 h at 37 ºC. 
Plates were treated with SRA737 (0.4 µM or 0.8 µM for A549 and SW620, 
respectively) or DMSO vehicle (0.004 % or 0.008% for A549 and SW620, 
respectively) in 100 µl medium and incubated for 84 h at 37 ºC. Plates were fixed 
and stained with SRB and read and analysed as described above. 
Knockdown experiments were carried out in 6-well plates using reverse transfection. 
siRNA and HiPerFect were added at 3 x the final assay concentrations (500 µl/well) 
and incubated for 20 min. Next, 500 µl of cells were added to each well and 
incubated for 6 h at 37 ºC. Medium (2 ml) was then added to each well to make 1 x 
siRNA and HiPerFect concentration and cells were incubated for 48 h at 37 ºC. 
Protein expression levels were determined by western blot. 
GI50 determinations for CHK1 inhibitors with POLA1, POLE and POLE2 
knockdown 
Cells were transfected with non-lethal concentrations of siRNA as described above. 
Plates were treated with 0.01 to 1 µM SRA737 or 0.1 to 10 µM MK-8776 for 84 h at 
37 ºC. Plates were fixed and stained with SRB and read and analysed as described 
above. Data were analysed using GraphPad Prism 6.0. 
Combination studies 
Cells were plated in 96-well plates at optimum seeding densities and incubated for 
36 h at 37 ºC. Plates were then treated with single agent SRA737 or aphidicolin, or a 
combination of the two, at a 1:1 ratio of each GI50 (previously determined) and 
incubated for four doubling times at 37 ºC. Plates were fixed and stained with SRB 
and read and analysed as described above. Data were analysed using the Chou and 
Talalay method to generate a combination index (CI, 24).  
High content analysis  
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Cells were plated in 96-well clear-bottom opaque-sided plates, incubated for 36 h at 
37 ºC and subsequently treated with a GI50 concentration of aphidicolin or SRA737 
or a combination of the two, followed by incubation for 24 h at 37 ºC. Gemcitabine at 
a final concentration of 200 nM was added as control. Cells were then fixed in 4% 
formaldehyde for 20 min and permeabilised with 0.25% Triton  X-100 for 10 min. 
Next, the fixed cells were blocked with 3% FBS in TNT for 1 h, incubated overnight 
at 4 ºC with a H2AX antibody (Upstate, USA #05636) at 1:500 and subsequently 
washed with PBS. The secondary antibody (Alexa Fluor 488 goat anti-mouse IgG, 
A11001 Invitrogen, USA) was added at 1:1000 for 1 h, cells were then washed, DAPI 
was added at 1:1000 for 5 min and cells were washed again before adding 200 µl 
PBS per well.  Images were acquired using an IN Cell Analyser 2200  and were 
analysed using IN Cell Analyser 1000 workstation (version 3.7.2, GE Healthcare Life 
Sciences, UK). 
Immunofluorescence studies 
A549 cells were plated onto 22x22mm coverslips (0.16-0.19mm thickness) in 6-well 
plates at 5x105 cells per well and incubated for 24 hours. Medium was removed and 
cells were preincubated with 1.9 ml fresh medium for one hour, after which 100µl of 
each drug was added at the required concentration. Cells were incubated for a 
further 24 hours. Medium was then removed, cells washed twice with phosphate-
buffered saline (PBS) and fixed with 4% paraformaldehyde (PFA) for 15 minutes at 
room temperature. PFA was removed and cells washed three times with PBS 
followed by permeabilisation in Tris-buffered saline (TBS) containing 3% Triton-X100 
for 15 minutes at room temperature. Permeabilised cells were washed twice in TBS 
before blocking in TBS containing 0.1% Tween (0.1%)  and 2% BSA (TBST/BSA) for 
1 hour at room temperature. Cells were incubated in Anti-phospho-Histone H2A.X 
(Ser139) Mouse primary antibody (EMD Millipore) at 1:2000 in TBST/BSA overnight 
at 4°C. Cells were then washed three times in TBST/BSA before incubation in Alexa 
Fluor 488 Donkey anti-Mouse secondary antibody (Invitrogen) at 1:1000 for one hour 
in the dark at room temperature. Cells were washed twice with TBST/BSA and then 
once with TBS. During this final TBS wash, two drops of NucBlueTM Live 
ReadyProbesTM Reagent (Invitrogen) were added per 1ml of TBS for each coverslip 
and incubated at room temperature in the dark for 20 minutes. After nuclear staining, 
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slides were mounted using ProLongTM Gold antifade Mountant (ThermoFisher) and 
left to dry overnight in the dark before imaging.  
Fixed sample slides were fitted onto an ASI motorised stage (ASI, Eugene, OR) and 
visualised using an Olympus IX71 microscope with PlanApo 100x OTIRFM-SP 1.45 
NA lens mounted on a PIFOC z-axis focus drive (Physik Instrumente, Karlsruhe, 
Germany), with illumination using LED light sources (Cairn Research Ltd, 
Faversham, UK) with appropriate filters (Chroma, Bellows Falls, VT). Samples were 
visualised using a QuantEM (Photometrics) EMCCD camera, and the entire system 
was controlled with Metamorph software (Molecular Devices). 3D-maximum 
projections of volume data were calculated from 31 z-plane images, each 0.2 µm 
apart. Data were subsequently analysed using Autoquant software 
(MediaCybernetics, Rockville, MD, USA). All 3D image stacks were subjected to 
blind 3D deconvolution before analysis. Number and intensity of foci were calculated 
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Results 
An siRNA screen identifies determinants of CHK1 inhibitor synthetic lethality 
To identify gene products whose loss is synthetically lethal with CHK1 inhibition, we 
performed an unbiased, large-scale siRNA screen with the developmental clinical 
drug  SRA737 and the Dharmacon druggable human genome siRNA library in 
human A549 NSCLC and SW620 colorectal cancer cells. These cell lines were 
selected due to their relatively low sensitivity to SRA737 (Supplementary Fig. 1), 
similar growth characteristics (i.e. doubling time and plating efficiency) and ease of 
transfection. In total, 6371 genes were screened with or without SRA737 in both cells 
lines, with three independent biological repeats per cell line. 
The screen was robust and reproducible, as shown by the fact that the WEE1 siRNA 
positive control (25) consistently sensitised A549 and SW620 cells to SRA737 and 
calculated were generally >0.5 (Fig. 1A and B) (23,26). Any plates with Z'- 
factors <0.5 were rejected from the analysis and re-run. Hits were identified as those 
genes with a difference in robust Z-score under control (0.004-0.008 % DMSO 
vehicle) and test (SRA737) conditions of  (Supplementary Tables 1 and 2; Fig. 1C 
and D). 
A number of the hits with the highest difference in robust Z-score encoded products 
that were associated with DNA replication (Fig. 1C and D), including MCM6 (mini-
chromosome maintenance complex component 6), RPA1 (replication protein A1), 
POLA1 (DNA polymerase , catalytic subunit), POLE (DNA polymerase , catalytic 
subunit) and POLE2 (DNA polymerase , accessory subunit). POLA1, POLE and 
POLE2 encode subunits of B-family DNA polymerases, responsible for high-fidelity 
DNA replication (27), and were identified as hits in both the A549 and SW620 cancer 
cell lines. POLA1, POLE and POLE2 met all the hit prioritisation criteria (see 
Materials and Methods section) and were therefore selected for further validation. 
Confirmation that knockdown of POLA1, POLE or POLE2 is synthetically lethal 
with CHK1 inhibition 
In order to confirm that knockdown of POLA1, POLE and POLE2 is synthetically 
lethal in the context of pharmacological CHK1 inhibition, cells were transfected with 
multiple siRNAs, each targeting a different region of the mRNA of each hit gene. 
Allstars negative (non-targeting) and positive death control siRNAs (Qiagen, USA) 
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were used as controls and to monitor transfection efficiency and toxicity. Both A549 
and SW620 human cancer cells were significantly sensitised to SRA737 by siRNA-
mediated depletion of POLA1 and POLE2 (Fig. 2A and B), while only A549 cells 
were also significantly sensitised to SRA737 by transfection with POLE siRNA (Fig. 
2A). Depletion of the cognate proteins by the siRNAs was confirmed even at the 
lowest concentrations tested (Fig. 2C and D). 
To quantify the extent to which depletion of POLA1, POLE or POLE2 could sensitise 
cancer cells to SRA737, we determined the GI50 values for SRA737 in both A549 
and SW620 cancer cell lines transfected with low concentrations of POLA1, POLE 
and POLE2 siRNA. Knockdown of POLA1, POLE or POLE2 significantly decreased 
the GI50 for SRA737 in both cancer cell lines, resulting in between 5- to 16-fold 
sensitisation to this CHK1 inhibitor drug (Fig. 3A-E). Importantly, we obtained similar 
results using MK-8776 (SCH 900776, 28), a second CHK1 inhibitor from a different 
chemotype to SRA737 (15), thus increasing the likelihood that the effects seen 
represent a genuine and specific synthetic lethal interaction between 
pharmacological inhibition of CHK1 function and depletion of B-family DNA 
polymerases (Supplementary Fig. 2A-C).  
To confirm that the synthetic lethal interaction that we observed involved an on-
target effect of SRA737, we performed CHK1 siRNA knockdown studies in 
combination with aphidicolin, a tetracyclic diterpene antibiotic which is a potent 
inhibitor of B-family DNA polymerases ,  and  (29-31). We found that A549 
cancer cells were indeed sensitised to aphidicolin treatment following siRNA-
mediated knockdown of CHK1 (Supplementary Fig. 3A), with reduction in CHK1 
protein expression confirmed by western blot (Supplementary Fig. 3B). 
Next, we investigated if the synthetic lethal interaction between POLA1, POLE or 
POLE2 knockdown and CHK1 inhibition could be seen in additional human NSCLC 
(NCI-H1975 and Calu-6) and colorectal cancer (HCT116 and RKO) cell lines. 
Encouragingly, all four additional cancer cell lines were significantly sensitised to 
SRA737 by POLE and POLE2 depletion (Supplementary Figs. 4A-D, 5A and B, 6A 
and B). Furthermore, NCI-H1975 and Calu-6 cells were significantly sensitised to 
SRA737 by transfection with POLA1 siRNA (Supplementary Figs. 4A and B). Note, 
however, that in both HCT116 and RKO colorectal cancer cell lines, transfection with 
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POLA1 siRNA alone markedly reduced cell number (Supplementary Fig. 4C and D), 
suggesting that these cell lines may have an absolute requirement for POLA1 and/or 
that knockdown was more efficient in RKO and HCT116 cells versus NCI-H1975 and 
Calu-6 NSCLC cells (Supplementary Figs. 5 and 6).  
Combined pharmacological blockade of CHK1 and B-family DNA polymerases 
synergistically inhibits cancer cell proliferation   
To confirm that the synthetic lethal interaction we observed was due to loss of both 
B-family polymerase and CHK1 catalytic activity, we adopted an orthogonal 
validation approach by performing combination studies using small-molecule 
inhibitors of both CHK1 and B-family DNA polymerases. We tested SRA737 in 
combination with aphidicolin in a panel of human cancer cell lines. We found that 
SRA737 and aphidicolin co-treatment was synergistic in 8 out of 9 cancer cell lines 
tested (Fig. 4A, Supplementary Table 3), including A549 lung and SW620 colorectal 
cancer cells (Fig. 4B and C).  
Clinical development of aphidicolin glycinate, a water-soluble analogue of 
aphidicolin, as an anticancer drug has been hampered by poor pharmacokinetics 
and toxicity (32). More recently, the structurally distinct retinoid-like agent CD437 has 
emerged as a DNA polymerase inhibitor with selectivity for over other B-family 
polymerases (33). Reassuringly, as with aphidicolin, synergy was also observed 
between SRA737 and CD437 in both the A549 NSCLC and SW620 colorectal 
cancer cell lines (Fig. 4D and E). Importantly, the synergy observed between 
SRA737 plus aphidicolin or SRA737 plus CD437 was comparable to that seen with 
the developmental clinical combination of SRA737 plus the chemotherapeutic agent 
gemcitabine (Supplementary Fig. 7A-D and Supplementary Table 3).  
In contrast to the results obtained in cancer cell lines, we found no synergy but only 
an additive effect for SRA737 combined with aphidicolin in the HBEC3-KT normal 
human bronchial epithelial cell line that is immortalized with CDK4 and hTERT (34, 
Supplementary Fig. 8). This would suggest that transformed cells may be more 
susceptible to this drug combination versus their non-transformed counterparts. 
Overall, our data demonstrate that pharmacological inhibitors of CHK1 and B-family 
DNA polymerases combine synergistically to inhibit cancer cell proliferation.  
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Combined depletion of CHK1 and the B-family DNA polymerases increases 
replication stress, DNA damage and apoptosis 
We hypothesised that combined loss of CHK1 and B-family DNA polymerase 
function would lead to enhanced replication stress, DNA damage and apoptosis. To 
test this, we examined RPA32 (Replication protein A 32 kDa subunit) which is 
phosphorylated at multiple sites in response to replication stress, an effect that can 
be visualised as a band shift on an immunoblot (7, 35-37). We observed an RPA32 
band shift after siRNA-mediated depletion of POLA1 alone, indicative of replication 
stress, but this was not visible with depletion of POLE or POLE2 alone in the A549 or 
SW620 cell lines (Fig. 5A). However, all combined treatments of SRA737 plus 
POLA1, POLE or POLE2 siRNA) induced a band shift in RPA32 (Fig. 5A). 
Furthermore, pharmacological inhibition of B-family polymerases with either 
aphidicolin or CD437 induced a detectable RPA band shift, which was further 
enhanced when combined with the CHK1 inhibitor SRA737 (Supplementary Fig. 9).  
Persistent and unresolved replication stress can lead to increased DNA damage and 
cell death (38). We found significantly higher levels of the DNA damage marker 
H2AX in 5 out of 6 cancer cell lines co-treated with the CHK1 inhibitor SRA737 and 
the B-family DNA polymerase inhibitor aphidicolin compared to either treatment 
alone, as detected by immunofluorescence using an IN Cell Analyser (Fig. 5B). We 
confirmed that the increase in H2AX signal was located in foci, which is indicative of 
direct DNA damage (Supplementary Fig. 10A-F). In addition, all combined 
treatments of SRA737 plus POLA1, POLE or POLE2 siRNA (apart from SRA737 
plus POLE2 depletion in SW620 cells), also caused an increase in the level of 
cleaved PARP (C-PARP), a marker of apoptosis, when compared to treatment with 
siRNA or SRA737 alone (Fig. 5A). Taken together, these data indicate that the 
combined inhibition of the DNA polymerases and CHK1 leads to enhanced 
replication stress, DNA damage and apoptotic cell death. 
POLA1, POLE and POLE2 protein expression correlate with single agent CHK1 
inhibitor sensitivity in human NSCLC and colorectal cancer cells lines  
Based on our results with depletion of B-family DNA polymerases, we hypothesised 
that cancer cells with lower levels of POLA1, POLE and POLE2 protein expression 
would be more sensitive to CHK1 inhibition compared to those with higher levels of 
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these polymerases. To test this, we measured the level of basal protein expression 
of POLA1, POLE and POLE2 in the panel of NSCLC and colorectal cancer cell lines 
(Fig. 6A, genetic status data Supplementary Table 4) and compared these data with 
GI50 values for single agent SRA737 treatment (Supplementary Table 5). We found a 
significant correlation between POLA1 and POLE protein expression and SRA737 
sensitivity (p  0.01), and between POLE2 protein expression and SRA737 
sensitivity (p  0.05) (Fig. 6B), suggesting that low basal expression of each of these 
proteins is indeed indicative of CHK1 inhibitor sensitivity. We also observed that the 
basal protein expression level of each of these polymerases correlated with the 
levels of the others (Supplementary Fig. 11A-D), consistent with reports that their 
expression is co-ordinated (39,40). In contrast, POLA1, POLE and POLE2 basal 
protein expression did not correlate with sensitivity to the combination of SRA737 
and aphidicolin (Supplementary Fig. 12A-C).   
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Discussion 
CHK1 inhibitors are currently in early clinical trials, both in combination with 
genotoxic agents and also as single agents (13,16). However, insights into tumour 
cell vulnerabilities that increase sensitivity to CHK1 inhibitors and biomarkers of this 
phenotype have been lacking. We used an unbiased large-scale siRNA screen to 
identify genes which are synthetically lethal when depleted in combination with 
CHK1 inhibition. We found that the knockdown of members of the B-family of DNA 
polymerases, POLA1, POLE and POLE2, sensitised human NSCLC and colorectal 
cancer cells to CHK1 inhibition. This synthetic lethal relationship was identified with 
the CHK1 inhibitor SRA737 and confirmed with the structurally distinct CHK1 
inhibitor MK-8776. Moreover, in addition to validation with multiple siRNAs, the 
interaction was seen with two chemically distinct B-family DNA polymerase 
inhibitors, namely aphidicolin and CD437, thus demonstrating the importance of 
catalytic inhibition. Note that such agreement between two distinct chemotype 
inhibitors is consistent with best practice for chemical probe use and provides 
greater confidence, alongside the orthogonal application of genetic depletion as also 
seen here, that the synthetic lethal interaction involves on-target effects on catalytic 
function (41). Importantly, we have demonstrated that the synthetic lethal interaction 
between CHK1 and the B-family DNA polymerases leads to a synergistic 
pharmacological effect and, moreover, we showed that this occurred in multiple 
human NSCLC and colorectal cancer cell lines. In addition, the synergy observed is 
comparable to that seen with the combination of SRA737 plus the chemotherapeutic 
agent gemcitabine that is currently undergoing clinical evaluation. Observing such 
robustness in the synthetic lethal interaction is very important and indicates that this 
effect is real and independent of the range of oncogenic abnormalities in the different 
cancer cell lines studied. The comparable synergy seen with inhibition of CHK1 plus 
B-family DNA polymerases and inhibition of CHK1 plus gemcitabine is encouraging, 
given that gemcitabine is typically considered as the most synergistic genotoxic drug 
for use in combination with CHK1 inhibition (18).  
A recent large-scale analysis has shown that robustness in synthetic lethal 
interactions is enriched in protein-protein interaction pairs (42). B-family DNA 
polymerases are responsible for the high-fidelity replication of DNA (27). Several 
studies have reported a functional relationship between these DNA polymerases and 
CHK1. Thus CHK1 has been shown to co-immunoprecipitate with DNA polymerase 
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 indicating a direct interaction between the two proteins (43). Some studies have 
indicated that is required for CHK1 activation (8, 44); conversely, 
other studies report that depletion of DNA poly  by siRNA leads to CHK1 
activation (43). Our own data herein show that depletion of the B-family DNA 
polymerases leads to a robust increased dependence of cancer cells on CHK1 
function.  
We hypothesised that combined loss of CHK1 and B-family DNA polymerase 
function leads to enhanced replication stress, DNA damage and apoptosis. This was 
confirmed by the presence of phosphorylated RPA, H2AX foci and PARP cleavage, 
respectively, which were all increased in human cancer cells following partial 
depletion of B-family DNA polymerases in combination with SRA737 treatment. 
Moreover, as mentioned, the synergy between SRA737 and aphidicolin or CD437 
was comparable to that seen with the combination of SRA737 plus gemcitabine in 
the NSCLC cell lines tested. Aphidicolin and CD347 both bind to the nucleotide 
binding site of the DNA polymerase, thus directly inhibiting polymerase activity 
(31,33). In contrast, gemcitabine inhibits the B-family DNA polymerases indirectly via 
two mechanisms: (i) depleting the pool of dNTPs available for DNA replication; and 
(ii) mis-incorporation into replicating DNA which generates lesions capable of stalling 
the B-family DNA polymerases (45). The shared inhibition of the B-family of DNA 
polymerases, albeit through a different molecular mechanism, almost certainly 
underlies the synergy seen with all three agents when combined with CHK1 
inhibition.  
It would be interesting to determine if CHK1 inhibitors are also effective in 
combination with other agents capable of inducing replication stress. Recently, the 
neddylation inhibitor MLN4924, which stabilises the re-replication factor CDT1 and 
potentially increases replication stress, has been shown to enhance the antitumour 
activity of the CHK1 inhibitor MK-8776, thus further supporting the hypothesis that 
inducing replication stress sensitises cancer cells to CHK1 inhibitors (46). Based on 
these findings and our own data, we propose a possible model for how the combined 
pharmacological inhibition of B-family DNA polymerases and CHK1 may increase 
replication stress, DNA damage and apoptotic cell death (Fig. 7). This suggests that 
CHK1 is required to alleviate the replication stress induced by loss of the B-family 
DNA polymerase function, possibly by stabilising stalled replication forks.  Thus, loss 
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of CHK1 when combined with depletion of B-family polymerases may cause 
intolerable levels of replication stress, DNA damage and eventual cell death. Further 
work is required to establish if this is the case. 
Germline and somatic mutations in DNA polymerase  (POLD1) and  (POLE) have 
been identified in a number of different cancers, particularly colorectal and 
endometrial (47). There are over 200 reported mutations in POLE occurring along 
the entire gene, of which few have been fully characterised and, to date, none have 
been associated with loss of the protein  perhaps unsurprisingly as DNA 
polymerase function is essential for viability. Interestingly, the high-mutation rates or 
hypermutator phenotype associated with colorectal and endometrial cancer have 
been attributed in part to mutations in the exonuclease domains of the DNA 
polymerases, leading to loss of their proofreading capabilities (47). We show here 
low POLA1, POLE and POLE2 protein expression correlate with sensitivity to CHK1 
inhibition. This is possibly because cancer cells expressing the B-family DNA 
polymerases at low levels are more sensitive to increases in replication stress. Thus, 
low expression of these polymerases at the protein level could potentially be used as 
biomarkers to predict patient sensitivity to CHK1 inhibitor monotherapy, although this 
needs to be confirmed with a large panel of cell lines and using clinical samples. In 
contrast, POLA1 POLE and POLE2 protein expression did not correlate with 
sensitivity to the combination of SRA737 and aphidicolin, perhaps because the 
pharmacological inhibition of B-family DNA polymerases ,  and  polymerase with 
aphidicolin overrides low level expression of B-family polymerases as a biomarker 
for this phenotype.  
It is interesting to compare our results to those obtained previously in relevant 
synthetic lethal screens. Hocke et al. (48) looked for genes that were synthetic lethal 
with ATR deficiency by screening an siRNA library corresponding to 288 DNA repair 
genes in a well-characterized genetic ATR knock-in model of DLD1 human colorectal 
cancer cells as compared to wild type counterparts. They identified as the strongest 
hit POLD1, which encodes the DNA polymerase catalytic subunit. Reasoning that 
CHK1 is the major downstream effector of ATR they used the staurosporine analog 
UCN-01 as an inhibitor of CHK1 and showed greater sensitivity in POLD1-depleted 
versus control cells. However, UCN-01 is known to be a non-selective inhibitor of 
CHK1 (49) and follow-up studies in additional colorectal cancer cell lines showed 
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that POLD1 knockdown resulted in a much smaller degree of sensitisation to UCN-
01, suggesting that the original finding in DLD1 cells was probably a cell line-specific 
observation. Moreover, although siRNAs targeting POLD1 were included in our own 
screen, as well as the screen reported by Davies et al. (25) of siRNAs to cell cycle 
and DNA repair genes looking for synthetic lethality with the CHK1 inhibitor 
AR458323 (and which identified WEE1 as synthetic lethal), POLD1 was not 
identified as a hit in either of these screens. The conflicting results with POLD1 likely 
reflect differences in the cancer cell lines and/or the CHK1 inhibitors used in the 
studies. In addition, POLA1 and POLE, both hits in our own screen, were not 
identified as synthetically lethal hits in the screen by Hocke et. al. (48) since siRNA 
against these genes proved lethal to DLD1 cells when applied on their own at 10nM. 
The findings we have reported here indicate that low concentrations of siRNA (less 
than 0.3 nM) can reduce polymerase levels sufficiently to see synthetic lethality with 
CHK1, but still leave enough residual activity for cells to survive under control 
conditions.  
In addition to our demonstration that low POLA1, POLE and POLE2 protein 
expression predispose cells to sensitivity to CHK1 inhibition, previous studies have 
indicated that amplification and/or elevated expression of MYC family genes may 
lead to CHK1 inhibitor sensitivity in a number of different cancer types (50, 51). For 
example, c-MYC overexpression predicts response to single agent treatment with 
the dual CHK1/CHK2 inhibitor LY2606368 in a panel of small cell lung cancer cell 
lines. This is thought to be due to the increase in replication stress associated with 
MYC overexpression (51). In addition, SRA737 has been shown to be effective as a 
single agent in vivo in mouse models of Eµ-MYC driven B-cell lymphoma and 
paediatric MYCN-driven neuroblastoma (14,15). Therefore it is conceivable that 
overexpression of other oncogenes associated with increased replication stress, 
such as Cyclin E or RAS (52), or replication-associated factors which allow cancer 
cells to cope with replication stress, such as CDT1 (53), could lead to CHK1 inhibitor 
sensitivity. Interestingly, a recent study has demonstrated that cyclin F loss 
predisposes cells to CHK1 inhibition by inducing DNA replication catastrophe (54). 
Moreover, other direct markers of replication stress, such as pRPA, pCHK1 and 
ssDNA, may also predict for CHK1 inhibitor sensitivity.  
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In conclusion, we have shown that both siRNA depletion and pharmacological 
inhibition of the B-family of DNA polymerases are synthetically lethal in combination 
with CHK1 inhibition in human lung and colorectal cancer cells. Combination studies 
revealed that the synergistic interactions between either of two B-family polymerase 
inhibitors aphidicolin and CD437 with the CHK1 inhibitor SRA737 were comparable 
to those seen with the promising combination of gemcitabine and SRA737 that is 
currently undergoing clinical evaluation.  Thus, the combination of B-family DNA 
polymerase inhibition with SRA737 could form the basis, subject to further follow up 
research, of a potential new future therapeutic approach. The clinical development of 
the water soluble aphidicolin analog, aphidicolin glycinate, was limited by its rapid 
clearance, low bioavailability and severe toxicity at the injection site and is no longer 
being pursued (32). The more recent retinoid-like agent CD437 has not reached the 
clinic and also inhibits the retinoic acid receptor  and potentially other off-targets as 
well as having non-optimized pharmaceutical properties (33). Thus the evaluation of 
the therapeutic potential of a CHK1 inhibitor in combination with a B-family DNA 
polymerase inhibitor in animal models and patients must await the emergence of 
suitable B-family DNA polymerase drug candidates, which the current work 
encourages. Finally, we found that low POLA, POLE and POLE2 protein expression 
could potentially be used as biomarkers to predict patient sensitivity to CHK1 
inhibitor monotherapy, which could, subject to confirmation and further validation, 
facilitate the effective clinical use of CHK1 inhibitors as single agents. 
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Figure Legends 
 
Figure 1: An siRNA screen identifies knockdown of DNA replication genes as 
synthetically lethal with CHK1 inhibition in human A549 NSCLC and SW620 
colorectal cancer cell lines.   
A and B Negative and positive control data for the siRNA library screen in  human 
NSCLC A549 cells (A) and  human colorectal cancer SW620 cells (B). Cell number 
is shown as a percentage of the mock control. Additional controls: Allstars negative 
siRNA (negative control for off target effects), WEE1 siRNA (positive control for 
synthetic lethality with SRA737) and death siRNA (positive control for transfection 
efficiency).  C and D The average difference in robust Z-score for A549 (C) and 
SW620 (D) cells transfected with siRNA and treated with either DMSO (vehicle 
control) or SRA737. Top hits common to both cell lines are shown as closed 
coloured circles. A-D Library siRNA (25nm) were introduced into cells by reverse 
transfection. Mock cells were transfected with lipid only. Cells were then incubated 
for 48 h followed by treatment with either vehicle (DMSO) control or SRA737 (0.4 or 
0.8 µM SRA737, A549 and SW620 respectively) for a further 84 h and then an SRB 
assay performed.  Each cell line was screened with the siRNA library three times (3 
biological repeats) to generate the data shown.  
Figure 2: Knockdown of POLA1, POLE and POLE2 expression is synthetically 
lethal in combination with CHK1 inhibition. 
A and B, The effect of POLA, POLE and POLE2 knockdown on cancer cell line 
sensitivity to SRA737. Human NSCLC A549 cells (A) and human colorectal cancer 
SW620 cells (B) were transfected for 48 h with siRNA with a range of siRNA 
concentrations per cell line as indicated in the figure and then treated with DMSO or 
SRA737 (0.4 or 0.8 µM SRA737, A549 and SW620 cells respectively) for a further 
fter which an SRB assay performed. Data analysed 
using the unpaired students t-test *p = <0.05, **p = <0.01. Results are shown as 
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mean ± SD C and D, Western blot analysis showing POLA1, POLE and POLE2 
knockdown in A549 (C) and SW620 (D) cells following transfection with 25 nM 
siRNA. GAPDH was used as a loading control. Blots have been cropped for clarity. 
 
 
Figure 3: POLA1, POLE or POLE2 knockdown lowers the GI50 value for SRA737 
in human NSCLC A549 and colorectal cancer SW620 cells. 
 A and B Concentration-response curves for SRA737 following transfection with 
POLA1, POLE or POLE2 siRNA in NSCLC A549 (A) and colorectal cancer SW620 
(B) cells. POLA1 (#3), POLE (#2) and POLE2 (#4) siRNAs were used at 0.1, 0.3 and 
0.3 nM respectively in A549 cells and at 1 nM in SW620 cells. Cells were transfected 
with siRNA for 48 h then treated with DMSO or SRA737 for a further 84 h. Mean cell 
number (  C and D, 
Plots of SRA737 GI50 values determined for A549 (C) and SW620 (D) cells, with 
summary (below the plots) of the mean GI50 values determined for SRA737 and the 
fold sensitisation to SRA737 as a result of siRNA transfection, relative to GI50 values 
determined for mock-
were compared using the unpaired students t-test. E, Chemical structure of SRA737.  
Figure 4: A synthetic lethal interaction between small-molecule inhibition of 
both CHK1 and DNA polymerases in human NSCLC and colorectal cancer cell 
lines. 
A Combination index (CI) values for NSCLC and colorectal cancer cell lines treated 
with 1 x GI50 
using the Chou and Talalay method. Bars indicate mean (  SD) CI values. A one-
sided students t-test was used to determine if mean CI values were significantly 
different from 1 (no interaction), *p = <0.05, **p = <0.01, ***p = <0.001. B and C 
Concentration-response curves showing the effect on cell numbers of aphidicolin, 
SRA737 and the combination treatment in NSCLC A549 (B) and colorectal cancer 
SW620 (C) cell lines (n = 3). D and E Concentration-response curves showing the 
effect on cell numbers of CD437, SRA737 and a combination treatment in A549 (D) 
and SW620 (E) cell lines (n = 3). B-E Data are mean (  SD) values of three 
biological replicates and shown relative to data from cells treated with a vehicle 
control.  
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Figure 5: Combined CHK1 and DNA polymerase inhibition increases 
replication stress and DNA damage in cancer cells 
 A Levels of RPA32 and C-PARP in the lysate of NSCLC A549 and colorectal cancer 
SW620 cells transfected with 0.1 nM (A549) or 1 nM (SW620) POLA1 #3, POLE #2 
or POLE2 #4 siRNA for 48 h prior to 24 h treatment with SRA737. A549 cells were 
treated with 0.4 µM SRA737 and SW620 cells with 0.8 µM.  RPA32 band shift is 
indicative of replication stress and C-PARP is a marker of apoptosis. GAPDH was 
used as loading control. Data are representative of two independent experiments. 
The blot has been cropped for clarity. B Mean (  SD) H2AX level, relative to that in 
untreated cells,  in cancer cells treated with aphidicolin, SRA737 alone or a 1:1 
combination of both agents for 24 h. H2AX levels were determined by 
-wise comparisons of 
levels in different treatment groups were carried out using an unpaired students t-
test, *p = <0.05, **p = <0.01, ***p = <0.001, ****p = <0.0001.  
Figure 6: Correlation between POLA and POLE basal expression and 
sensitivity to single agent CHK1 inhibition with SRA737. 
A Basal POLA1, POLE and POLE2 expression across a panel of human NSCLC 
and colorectal cancer cell lines. POLA/E/E2 expression was normalised to the 
loading control GAPDH. Data are representative of three independent experiments. 
The blot has been cropped for clarity. B Plots of basal POLA1, POLE and POLE2 
protein expression against SRA737 GI50, after western blots were scanned and 
50).  Black and grey dots 
indicate colorectal cancer and NSCLC cell lines respectively. Estimated regression 
line shown. Table shows  mean (SD) R2 values for POLA1, POLE or POLE2 protein 
expression versus SRA737 GI50 (n = 3). Data are representative of three 
independent experiments. 
Figure 7: Proposed model showing a potential mechanism for the synthetic 
lethal interaction between B-family DNA polymerase and CHK1 inhibition.   
Schematic illustrating the DNA replication fork under unperturbed conditions, after 
pharmacological inhibition of B family DNA polymerases, and following combined 
pharmacological inhibition of B-family DNA polymerase and CHK1.  
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